ASCO 2025: Adding Carboplatin Did Not Result in Statistically Significant Improvements in Patients With TNBC

by | Jun 4, 2025 | Myeloma News | 0 comments

Source: Pharmacy Times articles

New research finds that adding carboplatin to paclitaxel and adjuvant chemotherapy shows no significant survival benefits in triple-negative breast cancer (TNBC).
Read More

Submit a Comment